Langlois Sophia D. 4
4 · Keenova Therapeutics plc · Filed Feb 25, 2026
Insider Transaction Report
Form 4
Langlois Sophia D.
Director
Transactions
- Award
Restricted Stock Units
[F1][F2][F3]2026-02-23+3,984→ 8,866 total→ Ordinary Shares (3,984 underlying)
Footnotes (3)
- [F1]Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU.
- [F2]Each RSU will fully vest on February 23, 2027.
- [F3]Reflects that the Reporting Person received 820 additional RSUs resulting from the adjustment of the RSUs held by the Reporting Person immediately prior to the separation of Par Health, Inc. ("Par Health") from the Issuer on November 10, 2025, pursuant to the terms of the Employee Matters Agreement by and between the Issuer and Par Health.
Signature
/s/ Mark Tyndall, Attorney-in-Fact|2026-02-25